|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-2-26
|
|
pubmed:abstractText |
Capecitabine and gemcitabine given as fixed dose rate (FDR) has not been demonstrated to be well tolerated in phase I previous studies. The goals of this phase I study were to determine the maximum-tolerated dose of this combination and to describe the dose-limiting toxic effects (DLT) and the safety profile of this way of administration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
576-80
|
|
pubmed:meshHeading |
pubmed-meshheading:17158771-Adult,
pubmed-meshheading:17158771-Aged,
pubmed-meshheading:17158771-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17158771-Deoxycytidine,
pubmed-meshheading:17158771-Drug Administration Schedule,
pubmed-meshheading:17158771-Feasibility Studies,
pubmed-meshheading:17158771-Female,
pubmed-meshheading:17158771-Fluorouracil,
pubmed-meshheading:17158771-Humans,
pubmed-meshheading:17158771-Male,
pubmed-meshheading:17158771-Maximum Tolerated Dose,
pubmed-meshheading:17158771-Middle Aged,
pubmed-meshheading:17158771-Neoplasm Metastasis,
pubmed-meshheading:17158771-Neoplasms,
pubmed-meshheading:17158771-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
|
|
pubmed:affiliation |
Medical Oncology, University Campus Bio-Medico, Rome, Italy. d.santini@unicampus.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
